

# Daniele Pastori

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/649549/daniele-pastori-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

223  
papers

4,365  
citations

36  
h-index

55  
g-index

286  
ext. papers

5,891  
ext. citations

5.2  
avg, IF

6.01  
L-index

#	Paper	IF	Citations
223	Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , <b>2017</b> , 153, 480-487.e1	13.3	207
222	Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 949-956	7	129
221	Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 1325-36	3.4	116
220	Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. <i>Circulation</i> , <b>2012</b> , 126, 92-103	16.7	115
219	Platelet activation is associated with myocardial infarction in patients with pneumonia. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1917-25	15.1	105
218	Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	102
217	The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 4-11	3.3	99
216	Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. <i>Hepatology</i> , <b>2020</b> , 72, 470-485	11.2	90
215	Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events. <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 647-51	3	88
214	Oxidative stress and cardiovascular disease: new insights. <i>Kardiologia Polska</i> , <b>2018</b> , 76, 713-722	0.9	83
213	Features of severe COVID-19: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , <b>2020</b> , 50, e13378	4.6	74
212	Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2324-2331.e4	6.9	68
211	Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1832-1839	0.7	67
210	Atherothrombosis and Oxidative Stress: Mechanisms and Management in Elderly. <i>Antioxidants and Redox Signaling</i> , <b>2017</b> , 27, 1083-1124	8.4	66
209	A Simple Clinical Risk Score (CHEST) for Predicting Incident Atrial Fibrillation in Asian Subjects: Derivation in 471,446 Chinese Subjects, With Internal Validation and External Application in 451,199 Korean Subjects. <i>Chest</i> , <b>2019</b> , 155, 510-518	5.3	64
208	Gut-Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	60
207	Extra virgin olive oil use is associated with improved post-prandial blood glucose and LDL cholesterol in healthy subjects. <i>Nutrition and Diabetes</i> , <b>2015</b> , 5, e172	4.7	57

206	Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort. <i>Mayo Clinic Proceedings</i> , <b>2019</b> , 94, 1261-1267	6.4	57
205	The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 88-95	3.8	54
204	Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. <i>Chest</i> , <b>2015</b> , 147, 1644-1650	5.3	53
203	Modern approach to the clinical management of non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 8341-50	5.6	52
202	Extra virgin olive oil blunt post-prandial oxidative stress via NOX2 down-regulation. <i>Atherosclerosis</i> , <b>2014</b> , 235, 649-58	3.1	51
201	Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , <b>2015</b> , 201, 513-6	3.2	50
200	Localization of lipopolysaccharide from Escherichia Coli into human atherosclerotic plaque. <i>Scientific Reports</i> , <b>2018</b> , 8, 3598	4.9	50
199	Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. <i>International Journal of Cardiology</i> , <b>2018</b> , 264, 58-63	3.2	50
198	Long-term prediction of adherence to continuous positive air pressure therapy for the treatment of moderate/severe obstructive sleep apnea syndrome. <i>Sleep Medicine</i> , <b>2018</b> , 43, 66-70	4.6	47
197	Adherence to the Atrial Fibrillation Better Care Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients. <i>Thrombosis and Haemostasis</i> , <b>2021</b> ,	7	45
196	Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19. <i>Circulation Research</i> , <b>2020</b> , 127, 400-401	15.7	43
195	Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management. <i>Haematologica</i> , <b>2020</b> , 105, 562-572	6.6	43
194	Does Mediterranean Diet Reduce Cardiovascular Events and Oxidative Stress in Atrial Fibrillation?. <i>Antioxidants and Redox Signaling</i> , <b>2015</b> , 23, 682-7	8.4	41
193	Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease. <i>EBioMedicine</i> , <b>2015</b> , 2, 750-4	8.8	41
192	Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. <i>Scientific Reports</i> , <b>2018</b> , 8, 3702	4.9	40
191	Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1455-1462	15.1	39
190	ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. <i>American Journal of Medicine</i> , <b>2019</b> , 132, 856-861	2.4	39
189	Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 113, 617-24	7	38

188	Lipopolysaccharide as trigger of platelet aggregation via eicosanoid over-production. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1558-1570	7	36
187	Antioxidants for prevention of atrial fibrillation: a potentially useful future therapeutic approach? A review of the literature and meta-analysis. <i>Europace</i> , <b>2014</b> , 16, 1107-16	3.9	35
186	Aging-Related Decline of Glutathione Peroxidase 3 and Risk of Cardiovascular Events in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	34
185	PNPLA3 variant and portal/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress. <i>Scientific Reports</i> , <b>2017</b> , 7, 15756	4.9	34
184	Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review. <i>Medicine (United States)</i> , <b>2016</b> , 95, e2895	1.8	33
183	Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia. <i>Thorax</i> , <b>2015</b> , 70, 961-6	7.3	33
182	Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia. <i>Journal of Infection</i> , <b>2016</b> , 73, 107-14	18.9	32
181	Under-prescription of statins in patients with non-alcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2017</b> , 27, 161-167	4.5	32
180	Anoxia-reoxygenation enhances platelet thromboxane A2 production via reactive oxygen species-generated NOX2: effect in patients undergoing elective percutaneous coronary intervention. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2011</b> , 31, 1766-71	9.4	31
179	New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	31
178	Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. <i>International Journal of Cardiology</i> , <b>2015</b> , 180, 1-5	3.2	30
177	Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. <i>Internal and Emergency Medicine</i> , <b>2016</b> , 11, 199-204	3.7	30
176	Is there a clinical role for oxidative stress biomarkers in atherosclerotic diseases?. <i>Internal and Emergency Medicine</i> , <b>2014</b> , 9, 123-31	3.7	30
175	Nox-2 up-regulation and platelet activation: Novel insights. <i>Prostaglandins and Other Lipid Mediators</i> , <b>2015</b> , 120, 50-5	3.7	29
174	Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 866-875	7	27
173	Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000364	6	27
172	Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma. <i>Bioanalysis</i> , <b>2016</b> , 8, 275-83	2.1	26
171	Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 856-63	7	26

170	Risk factors for new-onset atrial fibrillation: A focus on Asian populations. <i>International Journal of Cardiology</i> , <b>2018</b> , 261, 92-98	3.2	24
169	Different behaviour of NOX2 activation in patients with paroxysmal/persistent or permanent atrial fibrillation. <i>Heart</i> , <b>2012</b> , 98, 1063-6	5.1	24
168	Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study. <i>American Journal of Hematology</i> , <b>2012</b> , 87, 384-7	7.1	23
167	Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 519-525	13.6	22
166	Mediterranean diet reduces thromboxane A2 production in atrial fibrillation patients. <i>Clinical Nutrition</i> , <b>2015</b> , 34, 899-903	5.9	22
165	Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition. <i>Trends in Cardiovascular Medicine</i> , <b>2014</b> , 24, 142-8	6.9	22
164	Is NOX2 upregulation implicated in myocardial injury in patients with pneumonia?. <i>Antioxidants and Redox Signaling</i> , <b>2014</b> , 20, 2949-54	8.4	22
163	Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. <i>American Heart Journal</i> , <b>2015</b> , 170, 490-7.e1	4.9	22
162	Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19. <i>Clinical and Translational Science</i> , <b>2020</b> , 13, 1071-1076	4.9	22
161	Corticosteroid Use and Incident Myocardial Infarction in Adults Hospitalized for Community-acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , <b>2019</b> , 16, 91-98	4.7	22
160	Atrial high-rate episodes and risk of major adverse cardiovascular events in patients with cardiac implantable electronic devices. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 96-102	6.1	22
159	Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician. <i>Therapeutic Advances in Gastroenterology</i> , <b>2018</b> , 11, 1756284818793561	4.7	21
158	Relation of nonalcoholic fatty liver disease and Framingham Risk Score to flow-mediated dilation in patients with cardiometabolic risk factors. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 1402-6	3	20
157	Low-grade endotoxemia, gut permeability and platelet activation in patients with impaired fasting glucose. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2017</b> , 27, 890-895	4.5	19
156	Inflammation and the risk of atrial high-rate episodes (AHREs) in patients with cardiac implantable electronic devices. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 772-777	6.1	19
155	Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , <b>2018</b> , 7,	5.1	19
154	Flow-mediated dilation is associated with cardiovascular events in non-valvular atrial fibrillation patients. <i>International Journal of Cardiology</i> , <b>2015</b> , 179, 139-43	3.2	18
153	Severity of OSAS, CPAP and cardiovascular events: A follow-up study. <i>European Journal of Clinical Investigation</i> , <b>2018</b> , 48, e12908	4.6	18

152	Gut-derived lipopolysaccharides increase post-prandial oxidative stress via Nox2 activation in patients with impaired fasting glucose tolerance: effect of extra-virgin olive oil. <i>European Journal of Nutrition</i> , <b>2019</b> , 58, 843-851	5.2	18
151	Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. <i>Pharmacological Research</i> , <b>2016</b> , 113, 484-489	10.2	18
150	Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis. <i>Clinical and Translational Gastroenterology</i> , <b>2015</b> , 6, e113	4.2	17
149	Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	17
148	Relationship of peripheral and coronary artery disease to cardiovascular events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , <b>2018</b> , 255, 69-73	3.2	17
147	Off-label use of ceftaroline fosamil: A systematic review. <i>International Journal of Antimicrobial Agents</i> , <b>2019</b> , 54, 562-571	14.3	17
146	Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 566-70	3.9	17
145	HIV-1 induces in vivo platelet activation by enhancing platelet NOX2 activity. <i>Journal of Infection</i> , <b>2015</b> , 70, 651-8	18.9	17
144	Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study. <i>BMJ Open</i> , <b>2015</b> , 5, e008026	3	17
143	Carotid plaque detection improves the predictive value of CHADS-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. <i>International Journal of Cardiology</i> , <b>2017</b> , 231, 143-149	14.2	16
142	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced Liver Disease: An Exploratory Meta-Analysis. <i>Hepatology Communications</i> , <b>2020</b> , 4, 1034-1040	6	16
141	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 1662-1668	3	15
140	The Role of Antioxidants Supplementation in Clinical Practice: Focus on Cardiovascular Risk Factors. <i>Antioxidants</i> , <b>2021</b> , 10,	7.1	15
139	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. <i>Atherosclerosis</i> , <b>2017</b> , 262, 179-184	3.1	14
138	Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 2455-2463	3.8	14
137	Nutrition, Thrombosis, and Cardiovascular Disease. <i>Circulation Research</i> , <b>2020</b> , 126, 1415-1442	15.7	14
136	Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 54, 34-39	3.9	14
135	Mechanisms And Management Of Thrombo-Embolic In Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , <b>2014</b> , 7, 1112	0.8	14

134	Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 508-515	3.8	14
133	Antiphospholipid syndrome and anticoagulation quality: a clinical challenge. <i>Atherosclerosis</i> , <b>2016</b> , 244, 48-50	3.1	13
132	Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e012596	6	13
131	Does Lysosomal Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 16, 28014-21	6.3	13
130	Total adiponectin is inversely associated with platelet activation and CHADSEVASC score in anticoagulated patients with atrial fibrillation. <i>Mediators of Inflammation</i> , <b>2014</b> , 2014, 908901	4.3	13
129	Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 4172-4180	5.6	13
128	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. <i>International Journal of Cardiology</i> , <b>2021</b> , 345, 7-13	3.2	13
127	Atrial high rate episodes in patients with cardiac implantable electronic devices: implications for clinical outcomes. <i>Clinical Research in Cardiology</i> , <b>2019</b> , 108, 1034-1041	6.1	13
126	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 379-387	3.7	13
125	Atrial high-rate episodes and thromboembolism in patients without atrial fibrillation: The West Birmingham Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , <b>2019</b> , 292, 126-130	3.2	12
124	SARS-CoV-2 and myocardial injury: a role for Nox2?. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 755-758	3.7	12
123	Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists. <i>Europace</i> , <b>2015</b> , 17, 1223-8	3.9	12
122	Stroke Care during the COVID-19 Pandemic: International Expert Panel Review. <i>Cerebrovascular Diseases</i> , <b>2021</b> , 50, 245-261	3.2	12
121	Nox2-mediated platelet activation by glycoprotein (GP) VI: Effect of rivaroxaban alone and in combination with aspirin. <i>Biochemical Pharmacology</i> , <b>2019</b> , 163, 111-118	6	11
120	Von Willebrand and Factor VIII Portosystemic Circulation Gradient in Cirrhosis: Implications for Portal Vein Thrombosis. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00123	4.2	11
119	Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naïve patients with atrial fibrillation. <i>American Heart Journal</i> , <b>2018</b> , 200, 32-36	4.9	11
118	Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , <b>2016</b> , 223, 619-624	3.2	11
117	Impaired flow-mediated dilation in hospitalized patients with community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , <b>2016</b> , 36, 74-80	3.9	11

116	Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2019</b> , 39, 2301-2308	7.9	11
115	Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease. <i>Internal and Emergency Medicine</i> , <b>2017</b> , 12, 1159-1165	3.7	11
114	PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation. <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	11
113	Relationship of Antiphospholipid Antibodies to Risk of Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 69, 561-576	4.3	10
112	Antioxidant activity from extra virgin olive oil via inhibition of hydrogen peroxide-mediated NADPH-oxidase 2 activation. <i>Nutrition</i> , <b>2018</b> , 55-56, 36-40	4.8	10
111	Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice. <i>Annals of Medicine</i> , <b>2018</b> , 50, 288-302	1.5	10
110	Aging and Adherence to the Mediterranean Diet: Relationship with Cardiometabolic Disorders and Polypharmacy. <i>Journal of Nutrition, Health and Aging</i> , <b>2018</b> , 22, 73-81	5.2	10
109	Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation. <i>Oncotarget</i> , <b>2016</b> , 7, 39143-39147	3.3	10
108	Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 658-665	6.4	10
107	Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, f11-f19	6.4	10
106	Blood hydrogen peroxide break-down activity in healthy subjects and in patients at risk of cardiovascular events. <i>Atherosclerosis</i> , <b>2018</b> , 274, 29-34	3.1	9
105	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. <i>Internal and Emergency Medicine</i> , <b>2018</b> , 13, 651-660	3.7	9
104	Is There an Interplay Between Adherence to Mediterranean Diet, Antioxidant Status, and Vascular Disease in Atrial Fibrillation Patients?. <i>Antioxidants and Redox Signaling</i> , <b>2016</b> , 25, 751-755	8.4	9
103	Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 3241-7	3.2	9
102	Serum albumin and risk of cardiovascular events in primary and secondary prevention: a systematic review of observational studies and Bayesian meta-regression analysis. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 135-143	3.7	9
101	Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.. <i>Lancet, The</i> , <b>2022</b> , 399, 1383-1390	4.0	9
100	Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study. <i>Thrombosis Research</i> , <b>2019</b> , 183, 28-32	8.2	8
99	A novel role of MMP2 in regulating platelet NOX2 activation. <i>Free Radical Biology and Medicine</i> , <b>2020</b> , 152, 355-362	7.8	8



98	Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort. <i>Atherosclerosis</i> , <b>2019</b> , 289, 195-200	3.1	8
97	Undifferentiated connective tissue disease - an unsolved problem: revision of literature and case studies. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2010</b> , 23, 271-8	3	8
96	Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 355-360	5.1	8
95	Antiphospholipid antibodies and lower extremity peripheral artery disease: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 1291-1298	5.3	8
94	Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study. <i>Cancer</i> , <b>2021</b> , 127, 2122-2129	6.4	8
93	C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP. <i>Scientific Reports</i> , <b>2017</b> , 7, 3797	4.9	7
92	Left Atrium Dilatation and Left Ventricular Hypertrophy Predispose to Atrial Fibrillation in Patients With Community-Acquired Pneumonia. <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 723-728	3	7
91	Quantifying Time in Atrial Fibrillation and the Need for Anticoagulation. <i>Progress in Cardiovascular Diseases</i> , <b>2018</b> , 60, 537-541	8.5	7
90	Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation. <i>Pharmacological Research</i> , <b>2018</b> , 132, 149-159	10.2	7
89	Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA). <i>Annals of Medicine</i> , <b>2018</b> , 50, 511-518	1.5	7
88	Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients. <i>Pharmacological Research</i> , <b>2021</b> , 165, 105418	10.2	7
87	Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renal disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design. <i>American Heart Journal</i> , <b>2017</b> , 189, 120-127	4.9	6
86	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 576-585	7	6
85	Cancer-specific ischemic complications in elderly patients with atrial fibrillation: Data from the prospective ATHERO-AF study. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 3424-3430	7.5	6
84	Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 588-593	4.5	6
83	Dementia and Atrial Fibrillation: A Dangerous Combination for Ischemic Stroke and Mortality. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 61, 1129-1132	4.3	6
82	Identifying At-Risk Patients for Sustained Atrial High-Rate Episodes Using the CHEST Score: The West Birmingham Atrial Fibrillation Project. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e017519 <sup>6</sup>	6	6
81	Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	6

80	The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 85, 80-85	3.9	6
79	Digoxin and Platelet Activation in Patients With Atrial Fibrillation: In Vivo and In Vitro Study. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009509	6	6
78	Low serum albumin levels and in-hospital outcomes in patients with ST segment elevation myocardial infarction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2021</b> , 31, 2904-2911	4.5	6
77	Antiphospholipid Antibodies and Autoimmune Haemolytic Anaemia: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	5
76	Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00116	4.2	5
75	Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. <i>Data in Brief</i> , <b>2018</b> , 17, 830-836 <sup>1,2</sup>	1.2	5
74	Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease. <i>BMC Infectious Diseases</i> , <b>2011</b> , 11, 341	4	5
73	Immunomodulatory effects of intravenous immunoglobulins (IVIg) in HIV-1 disease: a systematic review. <i>International Reviews of Immunology</i> , <b>2011</b> , 30, 44-66	4.6	5
72	Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , <b>2020</b> , 95, 513-520	6.4	5
71	Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2020</b> , 26, 1076029620945792	3.3	5
70	Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> ,	3.8	5
69	Update and Unmet Needs on the Use of Nonvitamin K Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation. <i>Current Problems in Cardiology</i> , <b>2021</b> , 46, 100410	17.1	5
68	Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. <i>International Journal of Cardiology</i> , <b>2021</b> , 327, 176-182	3.2	5
67	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 1583-1591	3.7	5
66	Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk?. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 383-384	3.3	5
65	Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 715878	5.4	5
64	Tailored Practical Management of Patients With Atrial Fibrillation: A Risk Factor-Based Approach. <i>Frontiers in Cardiovascular Medicine</i> , <b>2019</b> , 6, 17	5.4	4
63	Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	4

62	Nutritional and therapeutic approaches to modulate NADPH oxidase-derived ROS signaling in platelets. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 5945-50	3.3	4
61	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Biomedicines</i> , <b>2020</b> , 8,	4.8	4
60	Comparison of Anticoagulation Quality between Acenocoumarol and Warfarin in Patients with Mechanical Prosthetic Heart Valves: Insights from the Nationwide PLECTRUM Study. <i>Molecules</i> , <b>2021</b> , 26,	4.8	4
59	Cancer and atrial fibrillation: Epidemiology, mechanisms, and anticoagulation treatment. <i>Progress in Cardiovascular Diseases</i> , <b>2021</b> , 66, 28-36	8.5	4
58	A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 698008	5.6	4
57	Statins and non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2019</b> , 39, 1787	7.9	3
56	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. <i>Circulation Journal</i> , <b>2018</b> , 82, 1286-1292	2.9	3
55	Does the Coexistence of Chronic Obstructive Pulmonary Disease and Atrial Fibrillation Affect Nox2 Activity and Urinary Isoprostanes Excretion?. <i>Antioxidants and Redox Signaling</i> , <b>2019</b> , 31, 786-790	8.4	3
54	Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond. <i>Heart Failure Reviews</i> , <b>2021</b> , 1	5	3
53	Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study. <i>Thrombosis Research</i> , <b>2021</b> , 209, 69-74	8.2	3
52	Thrombosis in pre- and post-vaccination phase of COVID-19. <i>European Heart Journal Supplements</i> , <b>2021</b> , 23, E184-E188	1.5	3
51	Effects of Atrial Fibrillation and Chronic Kidney Disease on Major Adverse Cardiovascular Events. <i>American Journal of Cardiology</i> , <b>2020</b> , 132, 72-78	3	3
50	Clinical and pharmacological characteristics of elderly patients admitted for bleeding: impact on in-hospital mortality. <i>Annals of Medicine</i> , <b>2020</b> , 52, 413-422	1.5	3
49	Isoprostanes in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102821	13.6	3
48	Antiphospholipid Antibodies and Heart Failure with Preserved Ejection Fraction. The Multicenter ATHERO-APS Study. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
47	Atrial fibrillation pattern, left atrial diameter and risk of cardiovascular events and mortality. A prospective multicenter cohort study. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e13771	2.9	3
46	Anticoagulation in patients with advanced liver disease: an open issue. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 61-71	3.7	3
45	Predictors of Renal Function Worsening in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Multicenter Observational Study. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	3

44	The challenge of cardiovascular prevention in NAFLD. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 877-878	18.8	3
43	Lights and shadows in the management of old and new oral anticoagulants in the real world of atrial fibrillation by Italian internists. A survey from the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, e31-3	3.9	2
42	Reply. <i>Gastroenterology</i> , <b>2018</b> , 154, 761-762.e1	13.3	2
41	Direct oral anticoagulant reversal: how, when and issues faced. <i>Expert Review of Hematology</i> , <b>2017</b> , 10, 1005-1022	2.8	2
40	Lithiasis of semicircular canals and parotid glands: unusual stones deposition in atazanavir-treated individuals. <i>Aids</i> , <b>2009</b> , 23, 2233-4	3.5	2
39	Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 779503	5.4	2
38	Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 2063-2068	3.7	2
37	Relation of Atrial Fibrillation to Angiographic Characteristics and Coronary Artery Disease Severity in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , <b>2021</b> , 141, 1-6	3	2
36	Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	2
35	Lipopolysaccharide induces platelet activation in HIV patients: the role of different viral load patterns. <i>HIV Medicine</i> , <b>2021</b> , 22, 434-444	2.7	2
34	Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>Internal and Emergency Medicine</i> , <b>2019</b> , 14, 1199-1201	3.7	1
33	Antiphospholipid antibodies in end-stage renal disease: A systematic review and meta-analysis. <i>Hemodialysis International</i> , <b>2020</b> , 24, 383-396	1.7	1
32	Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication. <i>AIDS Research and Therapy</i> , <b>2011</b> , 8, 9	3	1
31	REPLY to "Association Between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome".. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2022</b> , 1	5.1	1
30	Serum albumin, clotting activation and COVID-19 severity: a systematic review and meta-regression analysis of 4579 patients <b>2021</b> , 10,		1
29	The Atrial Fibrillation Better Care (ABC) pathway in atrial fibrillation: a systematic review and meta-analysis of 285,000 patients. <i>Europace</i> , <b>2021</b> , 23,	3.9	1
28	Time to hospitalisation, CT pulmonary involvement and in-hospital death in COVID-19 patients in an Emergency Medicine Unit. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e14426	2.9	1
27	Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 695961	5.6	1

26	Sex-based difference in anticoagulated patients with mechanical prosthetic heart valves and long-term mortality risk. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e14064	2.9	1
25	Rivaroxaban for stroke prevention in people with atrial fibrillation and diabetes mellitus. <i>Diabetic Medicine</i> , <b>2018</b> , 35, 1134-1135	3.5	1
24	Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronization devices. <i>Europace</i> , <b>2021</b> ,	3.9	1
23	D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: asystematic review and metanalysis.. <i>Thrombosis Journal</i> , <b>2021</b> , 19, 102	5.6	0
22	Multiple Arterial Thrombosis in Seronegative Antiphospholipid Syndrome: Need for New Diagnostic Criteria?. <i>European Journal of Case Reports in Internal Medicine</i> , <b>2019</b> , 6, 001180	1.2	0
21	Family History of Atrial Fibrillation and Risk of Cardiovascular Events: A Multicenter Prospective Cohort Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2020</b> , 13, e008477	6.4	0
20	Nox2 up-regulation and hypoalbuminemia in patients with type 2 diabetes mellitus. <i>Free Radical Biology and Medicine</i> , <b>2021</b> , 168, 1-5	7.8	0
19	Impact of the New Metabolic-Associated Fatty Liver Disease (MAFLD) on NAFLD Patients Classification in Italy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2683-2684	6.9	0
18	Acute atrial ischemia associates with early but not late new-onset atrial fibrillation in STEMI patients treated with primary PCI: relationship with in-hospital outcomes. <i>Journal of Cardiology</i> , <b>2021</b> , 78, 368-374	3	0
17	Reply to: "Monitoring antivitamin K anticoagulants in antiphospholipid syndrome: A challenge in quality". <i>Atherosclerosis</i> , <b>2017</b> , 256, 148-149	3.1	
16	Response to "Digoxin or digoxin prescribed patient? Randomized trials are essential to discriminate the principal risk factor for the association of digoxin and increased mortality". <i>International Journal of Cardiology</i> , <b>2015</b> , 189, 247-8	3.2	
15	Obstructive Sleep Apnea and the Metabolic Syndrome: Pathophysiological and Clinical Evidence <b>2015</b> , 177-184		
14	Reply to "The relation between flow mediated dilation and atrial fibrillation" by S. Balta: Refers to Sevket Balta, MD et al. <i>International Journal of Cardiology</i> , <b>2015</b> , 201, 225-6	3.2	
13	Reply: LDL-Cholesterol and Atherosclerotic Cardiovascular Disease: Innocent Bystander or Essential Ingredient?. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 706-707	15.1	
12	Response to Duret et al. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 775-776	0.7	
11	Reply to: "Inadequate anticoagulation by vitamin K antagonists and major adverse cardiovascular events other than stroke". <i>International Journal of Cardiology</i> , <b>2016</b> , 202, 934-5	3.2	
10	Anticoagulants in Atrial Fibrillation and Liver Disease. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 2436	15.1	
9	Vitamin e serum level, a new tool to stratify bleeding risk in patients receiving oral anticoagulant therapy. <i>European Heart Journal</i> , <b>2013</b> , 34, P534-P534	9.5	

8	Vitamin e serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. <i>European Heart Journal</i> , <b>2013</b> , 34, P5606-P5606	9.5
7	Bleeding and mortality risk in patients implanted with mechanical prosthetic heart valves with and without thrombocytopenia. Insights from the nationwide PLECTRUM registry.. <i>Platelets</i> , <b>2022</b> , 1-6	3.6
6	Risk Scores for Death in Patients with Cancer-related Venous Thromboembolism: Still a Long Road Ahead. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 700-702	7
5	Short-term in vivo modifications of platelet NADPH oxidase 2 (NOX2) and prostaglandin F in HIV-1 patients on abacavir-based therapies. <i>HIV Medicine</i> , <b>2016</b> , 17, 774-777	2.7
4	T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation: A substudy from the ATHERO-AF cohort. <i>International Journal of Cardiology</i> , <b>2021</b> , 322, 245-249	3.3
3	Commentary on "Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial". <i>Hepatobiliary Surgery and Nutrition</i> , <b>2021</b> , 10, 699-701	2.1
2	Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study.. <i>Journal of Autoimmunity</i> , <b>2022</b> , 129, 102832	15.5
1	Clinical Phenotypes of Atrial Fibrillation and Mortality Risk: A Cluster Analysis from the Nationwide Italian START Registry. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12, 785	3.6